Related Experiment Videos

Combination therapy with beta-adrenergic receptor antagonists and phosphodiesterase inhibitors for chronic heart

Benjamin W Van Tassell1, Przemyslaw Radwanski, Matthew Movsesian

  • 1Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA. benjamin.vantassel@utah.edu

Pharmacotherapy
|November 26, 2008
PubMed

Insights

Phosphodiesterase inhibitors for heart failure increase cardiac output but also sudden cardiac death. Combining these drugs with beta-blockers may prevent adverse outcomes by targeting cyclic adenosine monophosphate signaling.

Area of Science:

  • Cardiology
  • Pharmacology
  • Molecular Biology

Background:

  • Phosphodiesterase (PDE) inhibitors are controversial in heart failure pharmacotherapy.
  • Clinical trials show PDE inhibitors increase cardiac output but also cardiovascular mortality and sudden cardiac death.

Purpose of the Study:

  • To investigate the potential of combining phosphodiesterase inhibitors with beta-adrenergic antagonists to mitigate adverse outcomes in heart failure.
  • To explore the role of cyclic adenosine 3',5'-monophosphate (cAMP) signaling compartmentation in myocardial response to combination therapy.

Main Methods:

  • Review of randomized clinical trials on phosphodiesterase inhibitors in heart failure.
  • Analysis of preliminary clinical and preclinical investigations into phosphodiesterase activity and signaling pathways.
  • Focus on the mechanism of cyclic adenosine 3',5'-monophosphate (cAMP) signaling compartmentation.

Main Results:

  • Phosphodiesterase inhibitors improve cardiac output but increase mortality.
  • Preliminary data suggest combination therapy with beta-adrenergic antagonists may prevent adverse events.
  • Cyclic adenosine 3',5'-monophosphate (cAMP) signaling compartmentation is a key factor.

Conclusions:

  • Combination therapy with phosphodiesterase inhibitors and beta-adrenergic antagonists shows promise for heart failure treatment.
  • Targeting cyclic adenosine 3',5'-monophosphate (cAMP) signaling pathways is crucial for optimizing cardiovascular outcomes.
  • Further research into PDE inhibitor and beta-blocker combination therapy is warranted.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...